Marizyme Stock Price, News & Analysis
MRZM
OTC
Company Description
Marizyme, Inc., a biotechnology company focused on life sciences, aims to develop therapies addressing acute care needs. Formerly known as GBS Enterprises, the company focuses on commercializing products like DuraGraft™ for CABG surgeries. With a recent FDA de novo clearance for DuraGraft™, Marizyme is set to revolutionize cardiac care.
Stock Performance
$—
0.00%
0.00
Last updated:
- %
Performance 1 year
$15.7M
Market Cap
131.8M
Shares outstanding
Latest News
SEC Filings
No SEC filings available for Marizyme.
Financial Highlights
—
Revenue (TTM)
—
Net Income (TTM)
—
Diluted EPS (TTM)
—
Operating Cash Flow
—
Net Profit Margin
—
Oper. Profit Margin
Upcoming Events
Frequently Asked Questions
What is the current stock price of Marizyme (MRZM)?
The current stock price of Marizyme (MRZM) is $0.0003 as of April 14, 2025.
What is the market cap of Marizyme (MRZM)?
The market cap of Marizyme (MRZM) is approximately 15.7M.
What is Marizyme, Inc. focused on?
Marizyme, Inc. is a biotechnology company dedicated to developing therapies that address critical needs in the acute care space.
What is the flagship product of Marizyme, Inc.?
The flagship product of Marizyme, Inc. is DuraGraft™, a solution indicated for adult patients undergoing CABG surgeries for the flushing and storage of saphenous vein grafts.
What recent achievement has Marizyme, Inc. accomplished?
Marizyme, Inc. received a de novo clearance from the FDA for DuraGraft™, making it the first and only FDA cleared medical device for use during CABG surgeries.
What is the potential impact of DuraGraft™ in cardiac care?
DuraGraft™ has the potential to change the landscape of cardiac care by reducing long-term mortality and maintaining the structural integrity of vascular conduits.
What is Marizyme, Inc.'s mission?
Marizyme, Inc. aims to present breakthrough solutions to cardiac surgeons and their CABG patients, with a focus on transforming cardiac care.